human
enteroviru
belong
enteroviru
genu
within
famili
picornavirida
genom
singlestrand
posit
sens
rna
approxim
nucleotid
consist
open
read
frame
flank
untransl
region
utr
intern
ribosom
entri
site
ire
depend
translat
initi
synthesi
viral
polyprotein
subsequ
cleav
structur
protein
nonstructur
protein
rna
genom
enclos
icosahedr
capsid
assembl
copi
four
structur
protein
first
describ
isol
twomonthold
infant
asept
mening
california
usa
sever
epidem
high
mortal
rate
occur
bulgaria
hungari
respect
sinc
mani
outbreak
report
taiwan
australia
singapor
malaysia
china
vietnam
cambodia
infect
usual
manifest
mild
hand
foot
mouth
diseas
hfmd
character
fever
mouth
ulcer
vesicl
palm
feet
unlik
hfmdrelat
enterovirus
also
caus
sever
neurolog
manifest
poliomyelitislik
acut
flaccid
paralysi
brainstem
enceph
infant
children
year
old
fatal
brainstem
enceph
character
rapid
progress
cardiopulmonari
failur
patient
neurolog
involv
surviv
often
perman
neurolog
sequela
delay
neurodevelop
reduc
cognit
function
similar
global
polioviru
pv
erad
initi
vaccin
like
effect
way
control
hope
erad
diseas
sever
promis
vaccin
candid
current
clinic
trial
nevertheless
effect
antivir
still
need
treatment
infect
patient
sever
diseas
review
highlight
potenti
target
antivir
well
recent
develop
futur
prospect
antivir
infect
similar
virus
infect
begin
initi
attach
attach
factor
present
cell
surfac
follow
interact
entri
receptor
enter
cell
clathrinmedi
endocytosi
uncoat
earli
endosom
viral
rna
undergo
iresdepend
translat
polyprotein
cleav
proteas
structur
nonstructur
protein
nonstructur
protein
mainli
involv
negativesens
positivesens
rna
synthesi
positivesens
viral
rna
pack
procapsid
final
matur
infecti
viral
particl
detail
replic
step
discuss
accord
therapeut
target
virushost
receptor
interact
first
essenti
event
viru
infect
abil
recogn
bind
specif
receptor
determin
host
rang
tissu
tropism
cell
surfac
carbohydr
heparan
sulfat
glycosaminoglycan
sialic
acid
often
target
pathogen
attach
factor
use
cell
surfac
heparan
sulfat
sialyl
glycan
attach
receptor
could
concentr
viru
host
cell
surfac
therefor
enhanc
infect
interact
entri
receptor
requir
initi
infect
two
function
import
entri
receptor
identifi
scaveng
receptor
class
pselectin
glycoprotein
express
cell
type
regard
major
entri
receptor
low
endosom
ph
need
induc
viral
uncoat
human
transgen
mice
infect
show
lethal
neurolog
manifest
patholog
featur
similar
human
monkey
suggest
contribut
pathogenesi
present
neutrophil
leukocyt
bind
enter
cell
caveolar
endocytosi
pathway
transgen
mice
express
human
fail
enhanc
infect
suggest
alon
contribut
pathogenesi
sinc
hostreceptor
interact
first
event
infect
inhibitor
block
event
could
act
potenti
therapeut
solubl
form
cellular
receptor
could
act
molecular
decoy
cellassoci
receptor
solubl
sialic
acid
heparin
heparin
mimet
demonstr
exhibit
inhibitori
effect
infect
vitro
highli
sulfat
suramin
analog
exhibit
antivir
activ
infect
mutant
consist
two
mutat
impli
inhibit
infect
bind
protein
similarli
kappa
carrageenan
sulfat
polysaccharid
seawe
also
exhibit
signific
antivir
activ
target
attach
entri
mechan
solubl
decoy
possibl
disrupt
integr
capsid
structur
steric
hindranc
receptor
interact
receptor
antagonist
could
also
develop
potenti
antivir
agent
peptid
deriv
design
peptid
found
exhibit
signific
antivir
activ
differ
strain
block
viral
attach
cell
surfac
heparan
sulfat
antiheparan
sulfat
peptid
previous
identifi
tiwari
et
al
also
inhibit
infect
anoth
antimicrobi
peptid
lactoferrin
also
exhibit
properti
vitro
vivo
block
viral
attach
cell
surfac
propos
uncoat
event
involv
attach
entri
receptor
trigger
seri
conform
chang
result
aparticl
format
prime
genom
releas
second
uncoat
event
occur
endocytosi
unknown
trigger
caus
rna
expuls
aparticl
via
axi
leav
behind
empti
capsid
format
aparticl
happen
presenc
receptor
low
ph
environ
suggest
aparticl
form
earli
endosom
uncoat
inhibitor
pocket
binder
intens
studi
antivir
agent
mani
picornavirus
includ
rhinoviru
pv
echoviru
coxsackieviru
complex
hydrophob
pocket
underneath
canyon
depress
recent
resolv
xray
crystallographi
key
success
factor
uncoat
inhibitor
abil
fit
hydrophob
pocket
stabil
capsid
structur
therefor
block
receptorinduc
uncoat
mechan
seri
modifi
win
compound
includ
effect
infect
valu
rang
nm
nm
howev
singl
point
mutat
suffici
confer
resist
modifi
win
compound
broad
spectrum
enteroviru
inhibitor
pleconaril
also
inhibit
infect
vitro
vivo
howev
pleconaril
fail
inhibit
cytopath
effect
induc
taiwan
isol
anoth
group
capsid
binder
pyridazinyl
oxim
ether
chemic
deriv
pirodavir
significantli
inhibit
infect
crystallograph
studi
show
pirodavir
predecessor
complex
rhinoviru
bind
hydrophob
pocket
underneath
canyon
floor
similar
mechan
win
compound
previous
identifi
antirhinoviru
compound
also
effect
infect
mechanist
studi
demonstr
bind
stabil
rhinoviru
heat
acid
inactiv
impli
act
viral
uncoat
inhibitor
protein
synthesi
commenc
translat
initi
capindepend
ire
element
genom
ire
cisact
element
form
tertiari
rna
structur
requir
assist
iresspecif
transact
factor
itaf
recruit
cellular
translat
machineri
viral
rna
open
read
frame
orf
translat
singl
polyprotein
subsequ
process
virusencod
proteas
structur
capsid
protein
nonstructur
protein
mainli
involv
replic
viral
rna
antisensemedi
mechan
consist
oligonucleotid
nucleotid
length
bind
rna
watsoncrick
base
pair
modul
function
target
rna
rna
interfer
rnai
involv
cleavag
target
mrna
rnainduc
silenc
complex
small
interf
rna
sirna
target
highli
conserv
region
significantli
inhibit
infect
dosedepend
manner
addit
short
hairpin
rna
shrna
effect
infect
vitro
vivo
use
sirna
clinic
set
hamper
short
halflif
plasma
improv
sirna
methyl
fluoro
modif
recent
demonstr
infect
howev
sirna
also
poor
endosom
uptak
limit
clinic
applic
sirna
translat
suppress
nucleotid
exampl
peptid
conjug
phosphodiamid
morpholino
oligom
ppmo
show
promis
result
inhibit
pv
coxsackieviru
unlik
sirna
shrna
ppmo
interact
target
rna
especi
ire
region
block
ribosom
recruit
therefor
inhibit
viral
rna
translat
ppmo
readili
penetr
cell
resist
nucleas
degrad
unpublish
data
confirm
pmo
highli
effect
compound
downregul
activ
iresdepend
translat
could
potenti
develop
antivir
agent
quinacrin
impair
iresdepend
translat
prevent
interact
polypyrimidinetract
bind
protein
ptb
ire
demonstr
act
infect
kaempferol
flavonoid
found
inhibit
ire
activ
alter
composit
itaf
geniposid
deriv
fructu
gardenia
inhibit
replic
via
inhibit
viral
ire
activ
amantadin
tricycl
symmetr
amin
previous
use
influenza
viru
infect
found
suppress
ire
translat
matur
cleavag
polyprotein
differ
viral
protein
critic
step
infect
proteas
key
proteas
cleav
viral
precursor
polyprotein
compon
protein
requir
viral
replic
packag
interestingli
proteas
suppress
type
interferon
target
mitochondri
antivir
signal
mav
protein
melanoma
differenti
associ
gene
viral
recognit
receptor
signal
sinc
proteas
involv
multipl
role
infect
evas
host
innat
immun
import
potenti
target
develop
antivir
therapeut
pseudosubstr
lvlqtm
peptid
could
inhibit
infect
bind
activ
site
proteas
rupintrivir
irrevers
peptidomimet
inhibitor
human
rhinoviru
proteas
reach
phase
clinic
trial
promis
outcom
rupintrivir
show
signific
inhibit
infect
vitro
vivo
reduc
efficaci
compar
human
rhinovirus
xray
crystallographi
complex
proteas
rupintrivir
reveal
halfclos
subsit
size
reduc
pocket
proteas
limit
access
rupintrivir
group
contain
lactam
ring
seri
proteas
rupintrivir
analogu
design
base
aldehyd
replac
ester
compound
significantli
inhibit
infect
oral
bioavail
proteas
inhibitor
design
compound
also
exhibit
antivir
activ
multipl
rhinoviru
serotyp
enterovirus
vitro
flavonoid
fisetin
rutin
also
identifi
proteas
inhibitor
genom
replic
enterovirus
shown
occur
membran
compart
cytoplasm
membran
vesicl
induc
pv
infect
report
associ
autophagi
signal
compart
resembl
autophagosom
consist
viral
protein
well
microtubuleassoci
protein
light
chain
membranebound
form
serv
marker
autophagi
induct
pv
infect
doublemembran
vesicl
consist
viral
particl
undergo
autophag
matur
typic
character
coloc
lysosomalassoci
membran
protein
similarli
induc
autophagi
format
rd
sknsh
cell
associ
autophagosomelik
vesicl
neuron
cervic
spinal
cord
mice
observ
author
conclud
autophag
signal
induc
crucial
replic
provid
altern
antivir
strategi
target
host
factor
relat
autophagi
crucial
viral
replic
discoveri
antivir
drug
mainli
base
viru
target
high
replic
mutat
rate
enterovirus
may
gener
resist
directact
antivir
target
host
factor
may
establish
higher
genet
barrier
resist
use
combin
viral
inhibitor
compound
inhibitor
shown
influenc
viral
yield
activ
pathway
host
cell
induc
autophagi
signal
downstream
transduc
pathway
compet
beclin
bind
autophagi
induct
may
impair
autophagi
activ
inhibit
pathway
thu
replic
requir
autophagosom
format
may
inhibit
presenc
compound
heat
shock
protein
beta
isom
report
crucial
role
entri
assembl
geldanamycin
ga
analog
inhibit
activ
protect
transgen
mice
challeng
inhibitor
target
host
factor
involv
cellular
autophagi
could
use
multipl
genotyp
enteroviru
serotyp
due
similar
pathway
replic
major
drawback
inhibitor
target
host
factor
specif
cellular
toxic
therefor
unmet
need
develop
specif
nontox
antivir
impair
cellular
autophagi
pathway
infect
amino
acid
sequenc
nonstructur
protein
highli
conserv
similar
pv
two
hydrophob
region
found
viral
protein
pv
pivot
viroporin
function
viroporin
mediat
integr
viral
protein
er
membran
increas
membran
permeabl
promot
viru
releas
studi
report
protein
might
mediat
chloridedepend
current
oocyt
chloridedepend
current
inhibitor
acid
did
report
inhibit
infect
rd
cell
viral
protein
pv
consist
walker
b
c
motif
homolog
motif
found
ntpbind
protein
member
helicas
superfamili
iii
amphipath
helix
domain
locat
ntermin
viral
protein
function
promot
oligomer
recent
two
antivir
compound
metrifudil
n
methyl
adenosin
block
replic
via
interact
viral
protein
precursor
protein
mutant
resist
metrifudil
mutat
viral
protein
mutant
doubl
mutat
viral
protein
howev
mechan
inhibit
yet
determin
deriv
benzimidazol
exhibit
antivir
activ
variou
enterovirus
identifi
target
picornavir
viral
protein
deriv
may
exert
potent
antivir
activ
sinc
pv
share
high
similar
nonstructur
protein
guanidin
hydrochlorid
extensivelystudi
picornaviru
inhibitor
inhibit
replic
pv
coxsackievirus
echovirus
footandmouth
diseas
viru
interestingli
guanidin
hydrochlorid
also
inhibit
infect
singl
mutat
protein
suffici
confer
resist
agent
like
prevent
associ
host
membran
structur
viral
replic
viral
protein
pv
contain
hydrophob
domain
facilit
bind
membran
vesicl
induc
viral
rna
replic
benzimidazol
deriv
enviroxim
exhibit
potent
activ
pv
rhinoviru
interact
viral
protein
strong
antivir
effect
enviroxim
shown
bifunct
inhibitor
enviroximelik
compound
also
target
inhibit
infect
effici
howev
precis
mechan
action
enviroxim
infect
remain
unknown
anoth
compound
identifi
potent
inhibitor
significantli
inhibit
infect
reduc
activ
viral
rna
replic
enterovirus
begin
linkag
genom
rna
protein
vpg
end
form
uridylyl
state
vpg
vpgpupu
addit
vpg
uridylyl
stimul
viral
precursor
protein
posit
strand
viral
rna
use
templat
synthes
neg
strand
turn
serv
templat
synthesi
new
posit
strand
synthesi
posit
neg
strand
viral
rna
prime
vpgpupu
nucleotid
site
rnadepend
rna
polymeras
rdrp
pivot
vpg
uridylyl
viral
rna
synthesi
mutat
impair
bind
vpg
rdrp
influenc
normal
rdrp
activ
ribavirin
convent
nucleosid
analogu
target
rdrp
picornavirus
ribavirin
inhibit
infect
prevent
induc
paralysi
death
mice
recent
piperazinecontain
pyrazolo
pyrimidin
deriv
shown
effect
target
rdrp
valu
suppress
accumul
posit
neg
strand
viral
rna
infect
mutant
mutat
rdrp
impli
interact
rdrp
inhibit
poli
u
elong
activ
vpg
uridylyl
figur
tabl
summar
potenti
target
antivir
list
recent
antivir
agent
signific
antivir
activ
infect
discuss
amongst
drug
modifi
win
compound
antivir
lowest
bovin
lactoferrin
pleconaril
shrna
sirna
rupintrivir
ribavirin
test
vivo
ribavirin
amantadin
alreadi
clinic
use
virus
rupintrivir
pleconaril
clinic
develop
avail
suitabl
anim
model
carri
requir
receptor
attach
factor
test
antivir
acceler
develop
antivir
clinic
use
antivir
agent
hamper
potenti
advers
effect
host
emerg
drug
resist
mutant
combin
therapi
target
differ
replic
step
infect
cycl
shown
synergist
activ
could
minim
emerg
antivir
resist
new
antivir
strategi
screen
licens
drug
infect
would
promis
clinic
use
newer
antivir
act
immunomodul
lethal
mutagen
offer
new
strategi
develop
antivir
endem
epidem
natur
continu
effort
develop
antivir
agent
prophylaxi
treatment
crucial
absenc
vaccin
togeth
effect
vaccin
erad
anticip
enteroviru
hfmd
hand
foot
mouth
diseas
ire
intern
ribosom
entri
site
itaf
iresspecif
transact
factor
mav
mitochondri
antivir
signal
melanoma
differenti
associ
gene
orf
open
read
frame
pv
polioviru
rdrp
rnadepend
rna
polymeras
vpg
viral
protein
genomelink
cwt
yfc
pend
patent
peptid
cwt
jkfl
ic
yfc
draft
manuscript
author
read
approv
final
manuscript
